777-48-0

Usage

Uses

Used in Pharmaceutical Industry:
3-nitro-4-fluoropropiophenone is used as an intermediate in organic synthesis for the production of pharmaceuticals. Its unique structure and reactivity allow for the development of various drug candidates with potential therapeutic applications.
Used in Agrochemical Industry:
3-nitro-4-fluoropropiophenone is also utilized as an intermediate in the synthesis of agrochemicals. Its chemical properties enable the creation of compounds that can be used in the development of pesticides and other agricultural products to improve crop yields and protect against pests.
Used in Fine Chemicals and Research Compounds:
3-nitro-4-fluoropropiophenone is used in the manufacturing of various fine chemicals and research compounds. Its versatility and reactivity make it a valuable component in the synthesis of specialty chemicals for research and development purposes.

Upstream product

• 456-03-1 1-(4-fluorophenyl)propan-1-one 
• 462-06-6 fluorobenzene 

Downstream Products

• 92554-10-4 3-Nitro-4-phenoxy-propiophenon 
• 90959-02-7 1-[10-(4-Chloro-phenyl)-9-oxy-3,4-dihydro-2H-1,4a,9-triaza-phenanthren-7-yl]-propan-1-one 
• 1716-57-0 6-Fluor-3-propyl-anilin 
• 90958-92-2 1-[4-(3,4-Dimethoxy-phenyl)-5-oxy-1,2-dihydro-imidazo[1,2-a]quinoxalin-7-yl]-propan-1-one 

Relevant academic research and scientific papers

Syntheses and In Vitro Anticancer Properties of Novel Radiosensitizers

Series of 4-(ethylsulfonyl)-1-halogen-2-nitrobenzene (3a-e) and 1-(4-halogen-3-nitrophenyl) propan-1-one (5a-d) analogs designed as novel radiosensitizers using bromonitropropiophenone and bromonitrobenzonitrile as lead compounds were synthesized. The anticancer activities of the compounds were evaluated in vitro using human prostate cancer (DU-145) and breast cancer (MCF-7) cell lines and the MTT assay. From the series, six compounds (3b-e, 5b-c) exhibited potent growth inhibitory effects against both cell lines. The most active, compound 3d, is an iodosulfone and is significantly more potent than the lead compound 5c at 10μm. Compounds were then compared with doxorubicin, a clinically used anticancer compound for breast and prostate cancers. Our most active compound 3d is more effective than doxorubicin at the dose level of 10μm at 3days after radiation, cell viabilities of 18%, 13% compared to 87%, 94% against MCF-7, and 15%, 20% compared to 60%, 75% against DU-145 without and with radiation, respectively. At 10μm, compound 5c had no effects as compared to control, whereas compound 3d reduced DU-145 cell viability to 16% and that of MCF-7 cells to 9% even at 5days after radiation. These results are very encouraging. Future studies include testing the compounds in vivo with and without radiation. Our most active compound 3d is significantly more effective than doxorubicin or lead compound 5c at the dose level of 10μm, without and with radiation; and in MCF-7 and DU-145 cell lines. These results are very encouraging. Future studies include testing the compounds in vivo without and with radiation.